|
刘建文 教授 博士生导师
--------------------------------------------------------------------------------
电话: 021-64252044 ;021-64252262
--------------------------------------------------------------------------------
传真: 021-64252044
--------------------------------------------------------------------------------
e-mail:
--------------------------------------------------------------------------------
个人简介
--------------------------------------------------------------------------------
刘建文,1994年毕业于上海中医药大学获得医学博士学位;1995年应日本国科学技术厅邀请,作为sta fellow在大阪生物科学研究所(osaka bioscience institute)和日本理化学研究所(institute of physical and chemical research)进行客座研究。研究天然药物对血管内皮细胞纤溶活性因子的基因调空作用。2001年毕业于日本广岛大学(省立)遗传子制御工学研究室,研究自由基与癌转移的过程及实验药物干预的分子机理,获得应用生物科学博士学位。现主要研究方向:细胞周期阻滞及凋亡诱导剂的发现与作用机理研究;肿瘤细胞凋亡小分子rna表达、调控的研究及其在新药研发中的应用;基于肿瘤光动力的分子模型的建立及先导化合物的发现研究。通过整体动物水平,离体细胞和分子水平研究新物质的药理药效学作用和机理,研究新物质对靶细胞作用后的蛋白水平,基因水平的影响,建立了以肿瘤学为主的分子细胞药理学研究特色。曾在国际肿瘤治疗学领域发现了通过抑制肿瘤细胞内的ros(reactive oxygen species),可以达到抑制癌细胞浸润转移的目的,该研究为开发非杀伤性抗癌转移的药物提出新的科学依据。论文被学术界引用和国际学术会议交流。主持国家和省部级科研课题。参与获得省部级科研成果一等奖2项、二等奖6项,三等奖3项申请发明专利11项,国际发明专利1项,发表国内外论文近140篇,其中sci收录82篇。主编《药理实验方法学—新技术与新方法》,《生物资源中活性物质的开发与利用》,参编《血管内皮细胞与疾病》,《生物抗氧化剂》(日文)。
--------------------------------------------------------------------------------
现主要研究领域:
分子、细胞生物学,医学肿瘤学,药理、毒理学,中药学
现主要研究方向:
1,细胞周期阻滞及凋亡诱导剂的发现与作用机理研究
2,肿瘤细胞凋亡下分子rna表达、调控的研究及其在新药研发中的应用
3. 基于肿瘤光动力的分子模型的建立及先导化合物的发现研究
4,生物抗氧化剂的应用基础研究
5. 纳米材料与技术在生命科学中的应用基础研究
获奖成果
-------
湖北省科研成果(1992年)三等奖
2006年度高等学校科学技术奖自然科学二等奖
2006年度上海市科技进步二等奖
2007年度上海医学科技奖三等奖
2007年度中华中医药学会科学技术奖三等奖
2013年度高等学校科学技术进步奖二等奖
2013年度上海市科技进步一等奖
2014年度高等学校科学研究 自然科学奖一等奖
2014年度高等学校科学研究 科技进步奖二等奖
2014年度中华医学科技奖 二等奖
2016上海中西医结合科学技术奖二等奖
主要出版编著
--------------------------------------------------------------------------------
1. 盛民立,刘建文 等: 《血管内皮细胞与疾病》 上海医科大学出版社(上海,1993, 12.)isbn 7-5627-0176-8/r.167
2. 三羽信比古,刘建文 等: 《生物抗氧化剂》日本fragrance杂志社 1999, 9, 30.(日文)isbn 4-89479-017-3
3. 刘建文 主编 《药理实验方法学—新技术与新方法》化学工业出版社生物医药出版中心(北京,2003.5)isbn 7-5025-3271-4
4. 三羽信比古,刘建文 等: 《美肤,皮肤防护与生物技术》日本cmc杂志社 2003.7(日文)isbn 4-88231-408-8
5.刘建文,贾伟主编《生物资源中活性物质的开发与利用》化学工业出版社(北京,2005.5)isbn 7-5025-7133-7
6. 李仪奎主编,刘建文 参编 《中药药理实验方法学》 上海科学技术出版社 (上海,2006.5)
7.刘建文 主编 《药理实验方法学—新技术与新方法》化学工业出版社生物医药出版中心(北京,2008.1第二版)isbn 978-7-112-01064-3/r.965.2
8.刘建文主编 《药理学》十一五国家重点图书,普通高等教育制药类专业规划教材,华东理工大学出版社(上海,2010.4)isbn 978-7-5628-2753-5/r.18
9. 陈奇主编,刘建文参编 《中药药理研究方法学》 人民卫生出版社 (北京2011.12)isbn 978-7-117-14398-1/r.14399
10.陈奇,张伯礼主编,刘建文参编《中药药效研究方法学》人民卫生出版社(北京2016.5)isbn 978-7-117-22052-1/r.22053
主要发表论文
1. wen xu, jianwen liu*, changlong li, he-zhen wu, yan-wen liu: kaempferol-7-o-β-d-glucoside (kg) isolated from smilax china l. rhizome induces g2/m phase arrest and apoptosis on hela cells in a p53-independent manner. cancer letters 2008,264: 229–240.
2. jin wang, aibin wu, yufang xu, jianwen liu*, xuhong qian* m2-a, a novel amonafide analogue, induces apoptosis and g2-m arrest via inhibiting pi3k/akt pathway on hl60 cells. cancer letters 2009,283:193–202.
3. mingcang chen, yiyi ye, jianwen liu,* guang ji hesperidin upregulates heme oxygenase-1 to attenuate hydrogen peroxide-induced cell damage in hepatic l02 cells. j. agric. food chem 2010, 58:3330–3335.
4. xin liang, yufang xu, ke xu, jianwen liu*, and xuhong qian. b1, a novel amonafide analogue, overcomes the resistance conferred by bcl
5. xin liang, aibin wu, yufang xu, ke xu, jianwen liu*, xuhong qian* :b1, a novel naphthalimide-based visible light activatable photonuclease, induces cell cycle arrest and apoptosis via chk2-p53 pathway in hela cells. invest new drugs 2011, 29, (4): 646-658.
6. xin liang , ke xu, yufang xu, jianwen liu* , xuhong qian: b1-induced caspase-independent apoptosis in mcf-7 cells is mediated by down-regulation of bcl-2 via p53 binding to p2 promoter tata box. toxicol appl pharm 2011,256 : 52–61.
7. ke shen, qiannan liang, ke xu, daling cui, lin jiang, peihao yin, yanhua lu, qi li, jianwen liu*: mir-139 inhibits invasion and metastasis of colorectal cancer by targeting the type i insulin-like growth factor receptor. biochem pharmacol 2012,84:320–330.
8. ke xu, xin liang, ke shen, daling cui, yuanhong zheng,jianhua xu, zhongze fan, yanyan qiu, qi li, lei ni, jianwen liu*: mir-297 modulate multidrug resistance in human colorectal carcinoma by down-regulating mrp-2. biochem j 2012, 446(2): 291-300.
9. ke xu, xin liang, ke shen, liyun sun, daling cui, yuxia zhao, jianhui tian, lei ni, jianwen liu*: mir-222modulatesmultidrug resistance in human colorectal carcinoma by down-regulating adam-17. exp cell res 2012, 318: 2168–2177.
10. ke xu, xin liang, daling cui, yixin wu, weibin shi and jianwen liu*: mir-1915 inhibits bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. mol carcinogen 2013, 52:70–78 .
11. ke shen, liyun sun, huanying zhang, yufang xu, xuhong qian, yanhua lu, qi li, lei ni, jianwen liu*:a ros-mediated lysosomal–mitochondrial pathway is induced by a novel amonafide analogue, 7c, in human hela cervix carcinoma cells. cancer letters 2013,333: 229–238.
12. ke shen, li ma, yi li, yanyan qiu, daling cui, yanhua lu, peihao yin, jianwen liu*: a post-transcriptional regulation of tumor suppressor mir-139-5p and a network of mir-139-5p mediated mrnas interactions in colorectal cancer. febs journal 2014, 281: 3609–3624.
13. yichun xu, shuai han, xinhua huang, shichao zhuo, huiqing dai, ke wang, zhou li, jianwen liu*. an effective method based on real time fluorescence quenching for single nucleotide polymorphism detection. journal of biotechnology 2014,186:156–161.
14. van-minh le, jing-jing wang, ming yuan, the-long nguyen, gui-fang ying, yuan-hong zheng, wei-bin shi, mei-dong lang, lei-ming xu, jianwen liu*: an investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles. european journal of medicinal chemistry 2015,92: 882-889.
15. yuanhong zheng, fangyuan zou, jingjing wang, guifang yin, vanminh le, zhewei fei, and jianwen liu*: photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through cd47 receptor protein. j biol chem. 2015, 290, 8975-8986.
16,rurong mao, fangyuan zou, liyan yang, shengchao lin, yueqi li, mingxing ma, peihao yin, xin liang, jianwen liu*: the loss of mir-139-5p promotes colitis-associated tumorigenesis by mediating pi3k/akt/wnt signaling int j biochem cell b 2015, 69:153–161.
17, shengchao lin, kecheng lei, wenpei du, liyan yang, haiyang shi, yuwei gao,
peihao yin, xin liang, jianwen liu*: enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ros-related mechanism. int j biochem cell b 2016,71: 24–34.
18. yuanhong zheng, guifang yin, vanminh le, anle zhang, peihao yin, jianwen liu*, photodynamic-therapy activates immune response by disrupting immunity homeostasis of tumor cells, which generates vaccine for cancer therapy int j biol sci 2016; 12(1): 120-132.
liyan yang, yue ding, peng zhang, jiyu li, xin liang*, jianwen liu*: targeted deletion of mir-139-5p enhances colon inflammation and tumorigenesis through negatively regulating mapk, nf-κb, and stat3 signaling pathwaysfebs journal, 2016, 283:1438-1452.
20.jie li, kecheng lei, zengrui wu, weihua li, guixia liu, jianwen liu*, feixiong cheng, yun tang: network-based identification of micrornas as potential pharmacogenomic biomarkers for anticancer drugs. oncotarget2016,7(29): 45584-45596.
21. lin zhou, xin liang2, lingling zhang, liyan yang, norio nagao, hongkun wu, chang liu, shengchao lin, guoxiang cai, jianwen liu*: mir-27a-3p functions as an oncogene in gastric cancer by targeting btg2. oncotarget 2016, 32(7): 51943-51954.
22. ke xu, ke shen, xin liang, yueqi li, norio nagao, jiyu li, jianwen liu*, peihao yin: mir-139-5p reverses cd44 /cd133 -associated multidrug resistance by downregulating notch1 in colorectal carcinoma cells oncotarget, 2016,7(46): 75118-75129.
23,xin liang, haiyang shi, liyan yang, cen qiu, shengchao lin, yingxue qi, jiyu li, aiguang zhao, and jianwen liu*: inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. br j cancer. 2017,116(7):903-911.
24,lei k, liang x, gao y , xu b, xu y , li y , tao y , shi w, liu j*. lnc-atb contributes to gastric cancer growth through a mir-141-3p/tgfβ2 feed back loop. biochemical and biophysical research communications 2017;484(3): 514-521.
地址:上海市徐汇区梅陇路130号 邮编:200237
800全讯白菜官方网站的版权所有 © 2023 华东理工大学药学院 |